(+)-Erinacin A
Based on 1 Customer Validation
(+)-Erinacin A (Erinacine A) is a cyanoditerpenoid isolated from Hericium erinaceus with anticancer, anti-inflammatory and neuroprotective activities. (+)-Erinacin A can induce cancer cell death by activating extrinsic and intrinsic apoptosis pathways. (+)-Erinacin A can also inhibit the expression of NO synthase (iNOS) and the production of nitrotyrosine to exert inflammatory and neuroprotective effects, thereby reducing ischemic brain damage.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.81%
- CAS 番号: 156101-08-5
- 分子式: C25H36O6
- 分子量:432.55
-
保管条件:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Caspase アイソフォーム固有の製品をすべて表示
More
生物活性
(+)-Erinacin A (30 μM; 3-24 h) activates the extrinsic and intrinsic apoptosis pathways in DLD-1 cells and reduces the expression of anti-apoptotic proteins[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DLD-1 Cells
-
Concentration:30 µM
-
Incubation Time:3-24 h
-
Result:Increased active forms of caspase-3, caspase-9 and caspase-8. Decreased the expression of the antiapoptotic proteins Bcl-2 and Bcl-XL. Upregulated the levels of phosphorylated JNK Thr183 and Tyr185, NFκB, and p300 proteins.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DLD-1 xenograft mouse model[5].
-
Dosage:1, 2 and 5 mg/kg
-
Administration:Intraperitoneal injection (i.p.) once a day for 5 days
-
Result:Inhibited tumor volume by 60%, 32% and 26%.
-
Animal Model:SAM rats with transient stroke[4].
-
Dosage:1, 5 and 10 mg/kg
-
Administration:Intraperitoneal injection (i.p.) single dose
-
Result:Induced NeuN immune response in the entire brain region of SAM rats, and increased the number of NeuN cells. Inhibited the activation of iNOS and p38/MAPK pathways and the expression of CHOP and nitrotyrosine proteins in rat brain tissue.
化学情報
-
CAS 番号 156101-08-5
-
性状 Solid
-
分子量 432.55
-
分子式 C25H36O6
-
Color Light yellow to yellow
-
SMILES
O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@](CC[C@]3(C)C4=C(C(C)C)CC3)(C)C4=CC=C(C=O)C2)OC1
-
別名
Erinacine A
-
Structure Classification
-
Initial Source
Hericium erinaceus
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
Ethanol : 10 mg/mL (23.12 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Bailly C, et.al. Erinacine A and related cyathane diterpenoids: Molecular diversity and mechanisms underlying their neuroprotection and anticancer activities. Pharmacol Res. 2020 Sep;159:104953. [Content Brief]
[2]. Tsai-Teng T, et al. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer’s disease-related pathologies in APPswe/PS1dE9 transgenic mice[J]. Journal of biomedical science, 2016, 23: 1-12. [Content Brief]
[3]. Prasher P, et al. Key oncologic pathways inhibited by Erinacine A: a perspective for its development as an anticancer molecule[J]. Biomedicine & Pharmacotherapy, 2023, 160: 114332. [Content Brief]
[4]. Lee K F, et al. Protective effects of Hericium erinaceus mycelium and its isolated erinacine A against ischemia-injury-induced neuronal cell death via the inhibition of iNOS/p38 MAPK and nitrotyrosine[J]. International journal of molecular sciences, 2014, 15(9): 15073-15089. [Content Brief]
[5]. Lee K C, et al. Induction apoptosis of erinacine A in human colorectal cancer cells involving the expression of TNFR, Fas, and Fas ligand via the JNK/p300/p50 signaling pathway with histone acetylation[J]. Frontiers in Pharmacology, 2019, 10: 1174. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.3119 mL | 11.5594 mL | 23.1187 mL | 57.7968 mL |
| 5 mM | 0.4624 mL | 2.3119 mL | 4.6237 mL | 11.5594 mL | |
| 10 mM | 0.2312 mL | 1.1559 mL | 2.3119 mL | 5.7797 mL | |
| 15 mM | 0.1541 mL | 0.7706 mL | 1.5412 mL | 3.8531 mL | |
| 20 mM | 0.1156 mL | 0.5780 mL | 1.1559 mL | 2.8898 mL |